← Back to Clinical Trials
Recruiting NCT05859113

Evaluation of Marginal Bone Loss and Associated Factors Around Ziacom Dental Implants With Different Prosthetic Connection

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Jaw, Edentulous, Partially
Sponsor Universidad de Granada
Study Type INTERVENTIONAL
Phase N/A
Enrollment 42
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2023-07-10
Completion 2025-12
Interventions
Ziacom Galaxy dental implant with internal connical prosthetic connectionZiacom Zinic dental implant with internal hexagonal prosthetic connection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Dental implants may suffer from bone loss around them, particularly at the upper portion where the prosthesis starts. The connection between both parts of the tooth restoration is key for avoiding micromovement during chewing, bacterial contamination and initiation of bone loss. Thus, investigating factors related to this bone loss in different types of implant-prosthetic connections is key for promoting better use of available therapeutics devices. In this study, we will study marginal bone levels over time as well as bacterial contamination and inflammatory markers in the peri-implant sulcus around implants with connical connection and compare them with those obtained when using implants with internal hexagonal connection. The hypothesis is that bone loss will be higher in implants with hexagonal connection associated with a pathological microbiome in the sulcus that induces a higher inflammatory response.

Eligibility Criteria

Inclusion Criteria: * One missing tooth in the premolar or molar area with both opposing and adjacent teeth (mesial and distal). Exclusion Criteria: * One-stage bone augmentation. * Uncontrolled type 1 or 2 diabetes (HgA1c\>8). * Known auto-immune or inflammatory disease. * Severe hematologic disorders, such as hemophilia or leukemia. * Local or systemic infection that may compromise normal healing (e.g., extensive periapical pathology). * Liver or kidney dysfunction/failure. * Currently receiving cancer treatment or within 18 months from completion of radio- or chemotherapy. * Long-term history of oral bisphosphonates use (i.e., 10 years or more). * History of intravenous bisphosphonates. * Long-term (\>3 months) history of antibiotics or drugs known to alter the inflammation and/or immunological system 3 months before inclusion. * Severe osseous diseases (e.g., Paget disease of bone). * Pregnant women or nursing mothers. * Not able or not willing to follow instructions related to the

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}